Injectable Drug Dropped From $375M Merger To Assuage FTC
By Matthew Perlman ( April 19, 2022, 5:19 PM EDT) -- The Federal Trade Commission reached a deal on Tuesday allowing Water Street Healthcare Partners to transfer a recently approved injectable steroid to a different portfolio company rather than include the treatment in its planned $375 million sale of Custopharm Inc. to Hikma Pharmaceuticals PLC....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.